In Brief: Abbott Laboratories/Home Access
This article was originally published in The Gray Sheet
Executive Summary
Abbott Laboratories/Home Access: Firms ink exclusive agreement to collaborate on development and marketing of home diagnostic tests employing Home Access' telemedicine test reporting and patient counseling service. Under the terms of the deal, Abbott will market tests to be developed by Home Access, which is responsible for gaining FDA approval and for providing related test result counseling services. Financial terms were not disclosed. Hoffman Estates, Illinois-based Home Access says that it is conducting research in the areas of genetics, cancer, drug testing, reproductive health and nutrition. The firm is currently the only company marketing FDA-approved at-home diagnostic tests with counseling services (telemedicine) -- the Home Access and Home Access Express HIV test systems. The firm notes that the home diagnostic tests under development likely will function along the same lines as the Home Access HIV test systems, which allow people to obtain the test sample at home and anonymously obtain the results by phone...
You may also be interested in...
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.
CRN Has Standing For Steep Hill To Climb Challenging New York's Age-Restricted Sales
Federal judge finds “misreading of the legislation” in CRN’s argument that state “restricts access based purely on what has been said about the product or its ingredients.” But standing to challenge “means that only CRN is positioned right now to go before the court on behalf of industry,” says CEO Steve Mister.
Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217
The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.